Inhaled insulin is recommended as a treatment option for people with type 1 or type 2 diabetes mellitus who have a haemoglobin A1c (HbA1c) level of 9% or higher, despite other therapeutic interventions (including appropriate diet and oral hypoglycaemic agents [OHAs]) and adequate educational support, and who are unable to start or intensify insulin therapy because of either: (1) a proven injection phobia diagnosed by a psychiatrist or psychologist, or (2) severe persistent problems with injection sites (for example, as a consequence of lipohypertrophy).[1]
